NasdaqGS - Nasdaq Real Time Price USD
AnaptysBio, Inc. (ANAB)
As of 1:19 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 12 |
| Avg. Estimate | -1.65 | -1.64 | -6.6 | -6.75 |
| Low Estimate | -1.99 | -2.01 | -7.36 | -8.47 |
| High Estimate | -1.04 | -1.03 | -5.69 | -5.17 |
| Year Ago EPS | -1.41 | -1.59 | -6.08 | -6.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 12 | 11 | 12 |
| Avg. Estimate | 6.87M | 7.59M | 32.06M | 32.45M |
| Low Estimate | -- | -- | 18.15M | -- |
| High Estimate | 11.2M | 13.24M | 41M | 70.83M |
| Year Ago Sales | 3.32M | 9.01M | 17.16M | 32.06M |
| Sales Growth (year/est) | 107.10% | -15.70% | 86.90% | 1.20% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.79 | -1.6 | -1.57 | -0.99 |
| EPS Actual | -1.41 | -1.59 | -1.64 | -1.71 |
| Difference | 0.38 | 0.01 | -0.07 | -0.72 |
| Surprise % | 21.20% | 0.60% | -4.50% | -72.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.65 | -1.64 | -6.6 | -6.75 |
| 7 Days Ago | -1.7 | -1.66 | -6.68 | -6.82 |
| 30 Days Ago | -1.7 | -1.66 | -6.68 | -6.82 |
| 60 Days Ago | -1.71 | -1.67 | -6.7 | -6.88 |
| 90 Days Ago | -1.72 | -1.65 | -5.9 | -6.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | ANAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -17.00% | -- | -- | 5.10% |
| Next Qtr. | -3.10% | -- | -- | 11.80% |
| Current Year | -8.60% | -- | -- | 2.10% |
| Next Year | -2.30% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/31/2024 |
| Maintains | UBS: Neutral to Neutral | 10/30/2024 |
| Maintains | Guggenheim: Buy to Buy | 10/21/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 9/26/2024 |
| Maintains | Truist Securities: Hold to Hold | 8/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2024 |
Related Tickers
TYRA Tyra Biosciences, Inc.
16.29
-2.34%
LXEO Lexeo Therapeutics, Inc.
8.03
+1.65%
IDYA IDEAYA Biosciences, Inc.
27.81
-1.21%
VERA Vera Therapeutics, Inc.
44.43
+10.03%
RVMD Revolution Medicines, Inc.
54.63
+2.11%
PCVX Vaxcyte, Inc.
106.17
-0.17%
BPMC Blueprint Medicines Corporation
89.55
+2.33%
ASND Ascendis Pharma A/S
123.92
+0.90%
SAGE Sage Therapeutics, Inc.
5.90
-3.04%
CORT Corcept Therapeutics Incorporated
47.17
-3.68%